Myeloma – The DREAMM-8 clinical trial that was presented at ASCO and published in the NEJM in June 2024 was a randomised trial comparing belantamab mafodotin, pomalidomide and dexamethasone (BPd) with pomalidomide, bortezomib and dexamethasone (PVd) in lenalidomide-exposed patients who had relapsed/refractory disease after at least one line of treatment. Patients randomised to BPd had deeper and more durable responses and a significantly better progression-free survival. BPd could be a further drug combination that is effective in lenalidomide refractory patients.
Myeloma – The DREAMM-8 clinical trial
